Drug Database
TA

tacrolimus (tacrolimus, Jina)

✓ Approved

Jina Pharmaceuticals, Inc. · FKBP1A

什么是 tacrolimus?

tacrolimus 是一种治疗药物,由Jina Pharmaceuticals, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)、Oral (PO)、Topical。

药物档案

商品名tacrolimus, Jina
公司Jina Pharmaceuticals, Inc.
分子靶点FKBP1A
给药途径Injectable (Others), Intravenous (IV), Oral (PO), Topical
状态Approved

作用机制

分子靶点

tacrolimus 作用于 1 个分子靶点:

FKBP1AFKBP prolyl isomerase 1A (FKBP-12, FKBP12)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

tacrolimus 针对 3 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Skin and subcutaneous tissue disordersDermatitis allergic✓ Approved
Skin and subcutaneous tissue disordersDermatitis atopic✓ Approved
Immune system disordersSolid organ transplant rejection✓ Approved

相关研究文献

PubMedFrontiers in immunology2026-11-17

HLA-DQ molecular mismatch predicts acute rejection and donor-specific antibody development after pediatric liver transplantation.

Trezeguet Renatti Guido G, Gamba Cecilia C, Arrigone Agostina A, Fernandez Souto Daniela D et al.

Prediction of alloimmune complications remains an unmet need in pediatric liver transplantation (PLT). Although HLA molecular mismatch (MM) has emerged as a promising biomarker in other solid organ transplants, current approaches rely on MM load, assuming that all MMs contribute equally to alloimmune risk. We aimed to evaluate the predictive value of MM, together with clinical and biochemical covariates, for biopsy-proven acute rejection (BPAR) and the development of de novo donor-specific antibodies (dnDSA) after PLT, and to assess the immunogenicity of individual MM units. A prospective cohort of 114 PLT recipients underwent high-resolution donor and recipient HLA typing. Clinical and MM-derived variables were evaluated as independent predictors using Cox proportional hazards models. Different MM approaches were evaluated, including individual HLA-DQ eplets and Snow-derived peptides, each encoded as a binary MM unit. Patient follow-up included surveillance and for-cause biopsies, together with dnDSA monitoring. Ridge-penalized Cox regression models were used to estimate the relative immunogenic contribution of each MM unit and to construct the outcome-specific epitope risk scores (BPAR-ERS and dnDSA-ERS). During follow-up, 67% and 32% of patients developed BPAR and dnDSA, respectively. HLA-DQ MM was significantly associated with both outcomes, although BPAR occurred significantly earlier than the first dnDSA detection (median [range], 0.97 [0.08-5.66] vs. 2.50 [0.78-5.50] years post-transplant; p<0.0001). Because HLA-DQ-specific dnDSA (dnDQ-DSA) was the predominant antibody specificity, subsequent analyses focused on this outcome. The eplet-derived BPAR-DQ-ERS and dnDQ-DSA-ERS outperformed conventional HLA-DQ eplet mismatch burden in predicting their respective outcomes. Patients in the highest ERS tertile exhibited significantly lower BPAR-free and dnDQ-DSA-free survival than those in the lower tertiles (both log-rank p<0.0001). In multivariable Cox regression analyses, BPAR-DQ-ERS (HR, 12.8; 95% CI, 5.0-33.0; p<0.0001) and variability in tacrolimus levels (HR, 4.5; 95% CI, 2.1-9.4; p<0.0001) were identified as independent predictors of BPAR. Independent predictors of dnDQ-DSA development were dnDQ-DSA-ERS (HR, 7.0; 95% CI, 3.3-14.8; p<0.0001) and previous BPAR (HR, 3.0; 95% CI, 1.1-8.1; p=0.0323). We identified HLA-DQ MM as an independent predictor of BPAR and dnDQ-DSA development. Importantly, the relative immunogenic contribution of each MM unit should be considered when personalizing post-transplant immunosuppression and PLT management.

PMID 43041229
阅读全文 →
PubMedThe pharmacogenomics journal2026-11-16

The impact of CYP3A5 genotype on tacrolimus pharmacokinetics in children following heart transplant.

Rower Joseph E JE, Freeman Tia S TS, Deering-Rice Cassandra E CE, Molina Kimberly M KM

Tacrolimus is a first-line immunosuppressant used after solid organ transplantation that suffers from extensive intra- and inter-patient variability and a narrow therapeutic window. Tacrolimus clearance is predominantly mediated by CYP3A4 and CYP3A5, with evidence indicating that pharmacogenetic (PG) differences in these enzymes drive significant changes in tacrolimus pharmacokinetics (PK) and therapeutic tacrolimus dosing. The current study investigates the hypothesis that CYP3A4/5 genetic variation alters tacrolimus dose requirement and metabolite concentration in children following pediatric heart transplant. Saliva and whole blood samples were collected from children who previously received a heart transplant as part of a tacrolimus PG/PK study. A total of 64 children were included in the analysis, which found that children carrying a CYP3A5*1 allele required a 2.7-fold higher tacrolimus dose (p < 0.0001) than individuals with the CYP3A5*3/*3 genotype. Weight-adjusted dose-normalized concentrations of tacrolimus (p < 0.0001) and its M-I (p = 0.0049) and M-II (p = 0.0043) metabolites were significantly lower in children with the CYP3A5*1 allele. Combined, these data support the impact of CYP3A5 genotype on tacrolimus PK and demonstrate the need for larger studies to confirm the clinical importance of this genotype for appropriate tacrolimus dosing in pediatric heart transplant recipients.

PMID 43035491
阅读全文 →
PubMedRinsho shinkeigaku = Clinical neurology2026-11-16

[A case of immune-mediated necrotizing myopathy complicated with immune thrombocytopenia successfully treated with intravenous immunoglobulin].

Kubo Hitoshi H, Yoshida Akira A, Ohtsubo Haruki H, Shiraoka Akira A et al.

A 41-year-old woman diagnosed with polymyositis had been treated with tacrolimus and repeated an intravenous immunoglobulin (IVIg) over past 14 years, due to worsening symptoms. Preadmission examinations showed thrombocytopenia. We diagnosed with immune thrombocytopenia (ITP) based on positive anti-platelet antibody and increased megakaryocytes on bone marrow examination. Following IVIg, both her muscle weakness and platelet counts normalized. The unique clinical course of this case prompted a reconsideration of her underlying muscular disease. Myopathological reexamination revealed predominantly necrotic and regenerating muscle fibers, and the presence of anti-HMGCR antibodies led to a revised diagnosis of immune-mediated necrotizing myopathy (IMNM) with ITP. Idiopathic inflammatory myopathy combined with ITP has been rarely reported. However, there are no prior reports of IMNM complicated with ITP. If thrombocytopenia is documented during the course of treatment in patients with IMNM, the complication of ITP should be taken into account when formulating the treatment strategy.

PMID 43035911
阅读全文 →
PubMedJournal of medical virology2026-11-16

Determinants of Torque teno virus Replication Across Early and Long-Term Post-Transplant Periods in a Large Multiorgan Transplant Population.

Bedo Dimitri D, Solis Morgane M, Gallais Floriane F, Renaud-Picard Benjamin B et al.

Torque teno virus (TTV) viral load is a promising biomarker for immune monitoring in solid organ transplantation, but interindividual variability limits its clinical interpretation. This study aimed to identify TTV viral load (TTV VL) determinants to improve its applicability. In this single-center cross-sectional study, TTV VL was measured between 2013 and 2021, in 477 kidney (KTR) and 240 lung transplant recipients (LTR). Factors associated with high TTV viral load, defined using the third-quartile cutoff (≥ 5.7 log10 copies/mL), were analyzed separately in KTRs and LTRs and in the pooled cohort. Mean TTV VL was 4.64 (1.94) log10 copies/mL, higher in LTR than KTR (5.04 vs. 4.44, p < 0.001). Female sex, an eGFR < 30 mL/min/1.73 m2, and shorter time since transplantation were independently associated with high TTV VL in both KTRs and LTRs. Additional independent associations in KTRs included tacrolimus, steroid, and rituximab exposure, a leukocyte count < 5.25 × 109/L and no history of cardiovascular event; in LTRs, they included greater immunosuppressive intensity, fibrosing interstitial lung disease, and a neutrophil count < 3 × 109/L. TTV VL reflects both immunosuppressive exposure and host-related determinants. Recognizing both is essential for interpreting TTV dynamics and defining individualized immunosuppression thresholds.

PMID 43038306
阅读全文 →
PubMedCurrent opinion in anaesthesiology2026-11-15

Postoperative acute kidney injury in thoracic noncardiac surgery: incidence, impact on outcomes, risk and protective factors, and evolving preventive strategies.

Ishikawa Seiji S, Kawagoe Izumi I

Postoperative acute kidney injury (AKI) significantly impairs short- and long-term clinical outcomes after thoracic noncardiac surgery, including increased mortality and prolonged hospitalization. This review synthesizes current evidence on the incidence, prognostic impact, risk factors, and evolving preventive strategies for AKI in thoracic surgery. Intraoperative fluid imbalance and hypotension are robust, modifiable risk factors for AKI. While goal-directed fluid therapy and machine learning-based Acumen Hypotension Prediction Index (Edwards Lifesciences, Irvine, California, USA) monitoring effectively optimize intraoperative hemodynamics and reduce hypotensive episodes, recent clinical trials and meta-analyses indicate they do not directly reduce postoperative AKI rates after general thoracic surgery. However, optimizing drug administration - such as continuous intravenous tacrolimus and shortened vancomycin duration - has demonstrated clinical benefit. Furthermore, evidence outside thoracic surgery demonstrates that the biomarker-guided Kidney Disease: Improving Global Outcomes care bundle significantly decreases moderate-to-severe AKI in high-risk surgical populations, suggesting potential applicability in thoracic surgical care. Given the multifactorial etiology of AKI, single hemodynamic interventions alone are insufficient for prevention. Perioperative care should integrate multimodality strategies, including optimal fluid and pressure management, pharmacological stewardship, and high-risk screening with care bundles. Further studies are needed to establish tailored preventive protocols, particularly for high-risk thoracic procedures such as lung transplantation and pneumonectomy.

PMID 43033141
阅读全文 →
PubMedClinical kidney journal2026-11-15

Sex dimorphism in vascular trajectories after living-donor kidney transplantation: a prospective exploratory cohort study.

Strizzi Camillo Tancredi CT, Arefin Samsul S, Hernandez Leah L, Raheman Awahan A et al.

Cardiovascular risk remains high after kidney transplantation, reflecting pre-transplant early vascular aging. Arterial stiffness generally improves, but the trajectory of microvascular endothelial function, and its dependence on recipient's biological sex and donor matching, is unclear. In 71 living-donor kidney transplant recipients, microvascular endothelial function (reactive hyperemia index, lnRHI) and arterial stiffness [augmentation index at 75 bpm (AI@75)] were measured before transplantation and at a median of 24.6 months. Forty-six of their donors were assessed identically before donation, providing a healthy reference of the same sex. Resistance arteries from 37 recipients and 46 living donors underwent wire myography. AI@75 improved overall (-5.7%; P = .003), whereas microvascular function declined in men but not women (male ΔlnRHI -0.149, P = .002; sex × time interaction β = -0.19, P = .026), stable in direction across 11 specifications including tacrolimus exposure and graft function. The greater AI@75 improvement with sex-matched transplantation (P = .020) did not survive adjustment for baseline stiffness (P = .32). Ex vivo, endothelial relaxation showed no detectable sex difference in recipients (P = .83) or donors (P = .94), whereas passive stiffness was higher in female recipients (P = .048). After living-donor kidney transplantation, arterial stiffness improved in both sexes, while microvascular endothelial function declined in men and not in women. Referenced to healthy donors of the same sex, arterial stiffness in men remained abnormal at follow-up. Sex-matched transplantation conferred no independent vascular benefit. These findings are exploratory and require confirmation in larger cohorts.

PMID 43032237
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多tacrolimus